GLP-1 Market
LLY $1381.18 ▼ -2.4% NVO $39.49 ▼ -3.0% PFE $28.07 ▼ -1.4% VKTX $26.19 ▼ -2.6% KLRA $11.89 ▼ -2.5% GPCR $17.36 ▼ -4.5% RHHBY $59.55 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Metformin XR

Company
Dexa Medica Group
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 18, 2026

Find a Clinical Trial Near Me

See recruiting studies for Metformin XR and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02915198

    Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

    Not yet reported VA Office of Research and Development 7410 participants Est. completion 2029-09-28 40 sites Stand-alone
    Other conditions: Prediabetic State, Atherosclerosis, Metformin
    View official trial listing →
  • Recruiting NCT NCT04939935

    Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

    Not yet reported The University of Queensland 1174 participants Est. completion 2030-12 49 sites Stand-alone
    Other conditions: Autosomal Dominant Polycystic Kidney Disease
    View official trial listing →
  • Recruiting NCT NCT05345327

    SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

    Not yet reported The George Institute 994 participants Est. completion 2026-06-30 8 sites
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06862739

    Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

    Not yet reported Nabiqasim Industries (Pvt) Ltd 800 participants Est. completion 2026-06-30 2 sites
    Other conditions: Diabetes Mellitus, Type 2 DM
    View official trial listing →
  • Recruiting NCT NCT07129473

    Hyperemesis Gravidarum Risk Reduction With Metformin

    Not yet reported, Not yet reported University of Southern California 224 participants Est. completion 2031-03 2 sites
    Other conditions: Hyperemesis Gravidarum
    View official trial listing →
  • Completed NCT NCT00068861

    Treatment of Infertility in Women With Polycystic Ovary Syndrome

    Not yet reported Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 678 participants Est. completion 2006-02 11 sites
    Other conditions: Polycystic Ovary Syndrome, Infertility, Pregnancy
    View official trial listing →
  • Completed NCT NCT00643851

    An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

    Not yet reported AstraZeneca 994 participants Est. completion 2009-08 99 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00683657

    Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

    Not yet reported AstraZeneca 93 participants Est. completion 2009-02 27 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00736385

    Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

    Not yet reported Duke University 11 participants Est. completion 2012-12 1 site
    Other conditions: Fatty Liver
    View official trial listing →
  • Withdrawn NCT NCT00775164

    Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study

    Not yet reported University of Minnesota Est. completion 2011-02
    Other conditions: Obesity, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00778622

    Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

    Not yet reported Bristol-Myers Squibb 371 participants Est. completion 2011-03 14 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00859898

    Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

    Not yet reported AstraZeneca 1093 participants Est. completion 2010-05 123 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00918138

    Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

    Not yet reported AstraZeneca 219 participants Est. completion 2010-05 21 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00960076

    An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 282 participants Est. completion 2010-10 35 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01002807

    Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

    Not yet reported AstraZeneca 15 participants Est. completion 2010-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01192139

    Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

    Not yet reported AstraZeneca 30 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01192152

    Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

    Not yet reported AstraZeneca 30 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01234649

    Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

    Not yet reported Woman's 153 participants Est. completion 2019-06-14 1 site Stand-alone
    Type 2 diabetesMetabolic syndromePrediabetes Other conditions: Gestational Diabetes Mellitus, Disorder of Glucose Regulation
    View official trial listing →
  • Completed NCT NCT01267448

    Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

    Not yet reported Cook County Health 100 participants Est. completion 2015-07-25 1 site
    Type 2 diabetes Other conditions: Hyperglycemia
    View official trial listing →
  • Withdrawn NCT NCT01305551

    BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

    Not yet reported AstraZeneca Est. completion 2011-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01365091

    Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

    Not yet reported AstraZeneca 112 participants Est. completion 2011-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01434186

    A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

    Not yet reported AstraZeneca 32 participants Est. completion 2016-04 16 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01441869

    Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

    Not yet reported AstraZeneca 28 participants Est. completion 2011-12 1 site
    Other conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
    View official trial listing →
  • Terminated NCT NCT01525225

    Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

    Not yet reported AstraZeneca 4 participants Est. completion 2013-06 7 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01557504

    A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

    Not yet reported Merck Sharp & Dohme LLC 25 participants Est. completion 2014-04-29 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01606007

    Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 1282 participants Est. completion 2014-01 139 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01725672

    Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

    Not yet reported GlaxoSmithKline 20 participants Est. completion 2013-08-21 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01733459

    Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

    Not yet reported Dexa Medica Group 124 participants Est. completion 2018-06 2 sites Stand-alone
    Other conditions: Polycystic Ovary Syndrome (PCOS)
    View official trial listing →
  • Completed NCT NCT01754142

    Korean Post-marketing Surveillance for Kombiglyze XR®

    AstraZeneca 755 participants Est. completion 2016-09-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01755494

    A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration

    Not yet reported AstraZeneca 64 participants Est. completion 2013-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01760447

    A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

    Not yet reported Merck Sharp & Dohme LLC 223 participants Est. completion 2019-09-17 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01765023

    Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects

    Not yet reported HK inno.N Corporation 80 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01809327

    A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

    Not yet reported Janssen Research & Development, LLC 1186 participants Est. completion 2014-12-02 129 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01864174

    Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

    Not yet reported Bristol-Myers Squibb 1736 participants Est. completion 2016-06-01 156 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01874080

    Bioequivalence Study

    Not yet reported AstraZeneca 56 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01975220

    Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

    Not yet reported Boehringer Ingelheim 72 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01999686

    PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

    Not yet reported Dexa Medica Group 186 participants Est. completion 2019-05 7 sites Stand-alone
    Other conditions: Polycystic Ovary Syndrome (PCOS), Insulin Resistance
    View official trial listing →
  • Completed NCT NCT02022007

    Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

    Not yet reported Woman's 38 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome, Disorder of Glucose Regulation
    View official trial listing →
  • Completed NCT NCT02039245

    Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

    Not yet reported Janssen Research & Development, LLC 12 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02065752

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

    Not yet reported Janssen Research & Development, LLC 2 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02071368

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

    Not yet reported Janssen Research & Development, LLC 3 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02073227

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

    Not yet reported Janssen Research & Development, LLC 52 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02077803

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

    Not yet reported Janssen Research & Development, LLC 47 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02106923

    Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

    Not yet reported Boehringer Ingelheim 72 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02145559

    A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors

    Not yet reported University of Chicago 24 participants Est. completion 2018-07 1 site Stand-alone
    Other conditions: Breast Neoplasms, Lung Neoplasms, Cancer of Liver, Lymphoma, Cancer of Kidney
    View official trial listing →
  • Completed NCT NCT02160743

    The Food Effect on Pharmacokinetics and Safety of Fixed-dose Combination of CJ-30056 in Healthy Male Subjects

    Not yet reported HK inno.N Corporation 28 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Food Effect Study of CJ-30056 20mg/500mg
    View official trial listing →
  • Completed NCT NCT02167061

    A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers

    Not yet reported Dong-A ST Co., Ltd. 64 participants Est. completion 2014-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02185066

    Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR

    Not yet reported HK inno.N Corporation 42 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02252965

    Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

    Not yet reported Merck KGaA, Darmstadt, Germany 532 participants Est. completion 2016-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02338193

    Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

    Not yet reported Woman's 69 participants Est. completion 2019-03-13 1 site Stand-alone
    Other conditions: Diabetes Prevention in Women After GDM Who Are at High-risk
    View official trial listing →
  • Completed NCT NCT02375139

    A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

    Not yet reported Dong-A ST Co., Ltd. 36 participants Est. completion 2015-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02637037

    A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

    Not yet reported AstraZeneca 80 participants Est. completion 2016-04-07 1 site Stand-alone
    Other conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
    View official trial listing →
  • Completed NCT NCT02738879

    Randomized Sitagliptin Withdrawal Study (MK-0431-845)

    Not yet reported Merck Sharp & Dohme LLC 746 participants Est. completion 2018-01-30 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02821910

    Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

    Not yet reported Boehringer Ingelheim 50 participants Est. completion 2016-10-31 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02846506

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02851095

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02851212

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02865668

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02895750

    Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

    Not yet reported Centre Hospitalier Universitaire, Amiens 12 participants Est. completion 2022-10-10 1 site
    Other conditions: Renal Insufficiency, Chronic
    View official trial listing →
  • Completed NCT NCT02911792

    Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

    Not yet reported The University of Texas Health Science Center at San Antonio 72 participants Est. completion 2023-07-11 2 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02967276

    Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma

    Not yet reported University of Campinas, Brazil 28 participants Est. completion 2020-02 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03038789

    XIGDUO Extended Release (XR) Post Marketing Surveillance

    AstraZeneca 623 participants Est. completion 2019-08-30 8 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03138356

    Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

    Not yet reported AstraZeneca 126 participants Est. completion 2017-11-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03169959

    A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

    Not yet reported AstraZeneca 85 participants Est. completion 2017-08-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03216278

    The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

    Not yet reported AstraZeneca 284 participants Est. completion 2018-05-22 1 site Stand-alone
    Other conditions: Healthy Subjects in Fasted and Fed State
    View official trial listing →
  • Completed NCT NCT03259490

    This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

    Not yet reported Boehringer Ingelheim 30 participants Est. completion 2017-11-13 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03467763

    Trial of an Intervention to Improve Metformin Persistence and Adherence

    Not yet reported Weill Medical College of Cornell University 13 participants Est. completion 2020-08-01 1 site
    Other conditions: Metformin Adverse Reaction, Tolerance
    View official trial listing →
  • Completed NCT NCT03629054

    This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

    Not yet reported Boehringer Ingelheim 30 participants Est. completion 2018-11-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT03710460

    Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

    Not yet reported University of Guadalajara 33 participants Est. completion 2023-12-30 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT03787017

    A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

    Not yet reported Handok Inc. 36 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03787043

    A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg

    Not yet reported Handok Inc. 30 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04047940

    A Study of LY900020 in Healthy Chinese Participants

    Not yet reported Eli Lilly and Company 32 participants Est. completion 2020-02-18 1 site
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT04511416

    Preventing Cognitive Decline with Metformin

    Not yet reported Garvan Institute of Medical Research 242 participants Est. completion 2027-12 1 site
    Other conditions: Cognitive Decline
    View official trial listing →
  • Terminated NCT NCT04530747

    Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea

    Not yet reported, Not yet reported Pennington Biomedical Research Center 16 participants Est. completion 2021-11-30 1 site Stand-alone
    Other conditions: Sleep Apnea, Obstructive
    View official trial listing →
  • Status unknown NCT NCT04667143

    Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 760 participants Est. completion 2022-10 Stand-alone
    Other conditions: Diabetes Mellitus, Type II
    View official trial listing →
  • Withdrawn NCT NCT04741204

    Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

    Not yet reported Woman's Est. completion 2022-09 1 site
    Other conditions: Breast Cancer Stage, Insulin Resistance, Racial Bias
    View official trial listing →
  • Active, not recruiting NCT NCT04850846

    Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 60 participants Est. completion 2027-07-31 7 sites Stand-alone
    Other conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04856007

    A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

    Not yet reported AstraZeneca 80 participants Est. completion 2021-06-14 1 site Stand-alone
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Terminated NCT NCT04899349

    Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

    Not yet reported Novartis Pharmaceuticals 2 participants Est. completion 2023-05-10 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05093959

    Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

    Not yet reported Wake Forest University Health Sciences 86 participants Est. completion 2026-04-16 2 sites
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05440591

    Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

    Not yet reported Tan Tock Seng Hospital 150 participants Est. completion 2023-05-10 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT05628584

    High FODMAP Diet With Metformin in preDM

    Not yet reported Elaine Chow 26 participants Est. completion 2023-10-15 1 site Stand-alone
    Prediabetes
    View official trial listing →
  • Status unknown NCT NCT05952882

    Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

    Not yet reported Mỹ Đức Hospital 188 participants Est. completion 2025-12-31 Added to GLP-1
    Other conditions: Polycystic Ovary Syndrome, Obesity, Infertility, Female
    View official trial listing →
  • Completed NCT NCT06128967

    A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

    Not yet reported Cardresearch 399 participants Est. completion 2025-08-01 6 sites
    Other conditions: Long COVID-19 Syndrome, Chronic Fatigue Syndrome
    View official trial listing →
  • Completed NCT NCT06327815

    Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

    Not yet reported AstraZeneca 633 participants Est. completion 2025-06-30 35 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07026968

    A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 815 participants Est. completion 2026-11-13 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07139405

    TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

    Not yet reported Myopharm Limited 48 participants Est. completion 2027-12-30 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07213895

    Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

    Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-09-18 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07323381

    Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

    Not yet reported Bin Lu 116 participants Est. completion 2027-09-30 Stand-alone
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT07399535

    Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome

    Not yet reported Jinnah Postgraduate Medical Centre 116 participants Est. completion 2026-03-01 1 site Stand-alone
    Other conditions: Polycystic Ovarian Syndrome (PCOS), Herbal Medicine, Infertility, Metabolic Disorder
    View official trial listing →
  • Completed NCT NCT07603505

    Effect of NAE on Polycystic Ovarian Syndrome (PCOS)

    Not yet reported Jinnah Sindh Medical University 116 participants Est. completion 2026-06-15 1 site Stand-alone
    Other conditions: Polycystic Ovarian Syndrome (PCOS), Infertility, Metabolic Disorders
    View official trial listing →
  • Not yet recruiting NCT NCT07622290

    Metformin Treatment for Children With Obesity-associated Asthma

    Not yet reported Prof Ibrahim Janahi 182 participants Est. completion 2028-03 1 site
    Other conditions: Obesity-associated Asthma
    View official trial listing →
  • Completed NCT NCT07937449

    The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

    Not yet reported Dexa Medica Group 120 participants Est. completion 2026-10-15 2 sites
    Prediabetes
    View official trial listing →
  • Completed NCT NCT07945496

    Bioequivalence of Dapagliflozin and Metformin Extended-release Tablets Versus XIGDUO® XR in Healthy Adult Subjects

    Not yet reported The Affiliated Hospital of Qingdao University 78 participants Est. completion 2023-11-01 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.